$2.31 Billion is the total value of Vivo Capital, LLC's 59 reported holdings in Q2 2021. The portfolio turnover from Q1 2021 to Q2 2021 was 33.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ASND | Sell | Ascendis Pharma A/Ssponsored adr | $200,793,000 | -6.4% | 1,526,359 | -8.3% | 8.69% | +15.3% |
| AMRS | Sell | Amyris, Inc | $190,546,000 | -24.2% | 11,639,929 | -11.6% | 8.25% | -6.6% |
| TARS | Sell | Tarsus Pharmaceuticals Inc | $86,573,000 | -17.2% | 2,987,331 | -7.9% | 3.75% | +2.0% |
| EPIX | Sell | Essa Pharma Inc | $44,331,000 | -26.2% | 1,551,680 | -25.0% | 1.92% | -9.1% |
| LEGN | Sell | Legend Biotech Corp Sponsoredsponsored ads | $39,273,000 | -50.9% | 956,702 | -65.3% | 1.70% | -39.5% |
| CRNX | Sell | Crinetics Pharmaceuticals Inc | $33,032,000 | -2.4% | 1,752,346 | -20.9% | 1.43% | +20.3% |
| CLDX | Sell | Celldex Therapeutics Inc | $32,400,000 | +21.7% | 968,906 | -25.0% | 1.40% | +50.1% |
| ACRS | Sell | Aclaris Therapeutics, Inc. | $24,132,000 | -41.9% | 1,374,279 | -16.6% | 1.04% | -28.4% |
| NVAX | Sell | Novavax Inc | $18,693,000 | -34.5% | 88,046 | -44.1% | 0.81% | -19.4% |
| GRCL | Sell | Gracell Biotechnologies Incsponsored ads | $17,267,000 | -26.4% | 1,328,257 | -12.8% | 0.75% | -9.3% |
| KDNY | Sell | Chinook Therapeutics Inc | $12,315,000 | -34.3% | 872,151 | -27.7% | 0.53% | -19.1% |
| ARQT | Sell | Arcutis Biotherapeutics Inc | $11,833,000 | -45.1% | 433,585 | -41.8% | 0.51% | -32.4% |
| PASG | Sell | Passage Bio Inc | $8,553,000 | -65.4% | 646,001 | -54.3% | 0.37% | -57.4% |
| CALT | Sell | Calliditas Therapeutics ADRsponsored ads | $1,835,000 | -78.6% | 62,306 | -80.0% | 0.08% | -73.8% |
| IGMS | Exit | IGM Biosciences Inc | $0 | – | -20,000 | -100.0% | -0.05% | – |
| VYNE | Exit | VYNE Therapeutics Inc | $0 | – | -234,877 | -100.0% | -0.06% | – |
| CNST | Exit | Constellation Pharmaceutical | $0 | – | -140,298 | -100.0% | -0.12% | – |
| ATRC | Exit | Atricure Inc | $0 | – | -64,573 | -100.0% | -0.15% | – |
| KALA | Exit | Kala Pharmaceuticals, Inc. | $0 | – | -786,883 | -100.0% | -0.19% | – |
| CGEM | Exit | Cullinan Management Inc | $0 | – | -250,000 | -100.0% | -0.37% | – |
| AKRO | Exit | Akero Therapeutics Inc | $0 | – | -673,280 | -100.0% | -0.69% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-08-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ACLARIS THERAPEUTICS INC | 29 | Q3 2023 | 33.5% |
| CODEXIS INC | 29 | Q3 2023 | 8.0% |
| ASCENDIS PHARMA A/S | 25 | Q3 2022 | 24.0% |
| KALVISTA PHARMACEUTICALS INC | 25 | Q3 2023 | 3.9% |
| Verona Pharma PLC ADR | 24 | Q3 2023 | 7.6% |
| AMYRIS INC | 23 | Q3 2023 | 8.8% |
| EIGER BIOPHARMACEUTICALS INC | 23 | Q1 2022 | 8.7% |
| Zai Lab Ltd ADR | 22 | Q3 2023 | 1.8% |
| Arrowhead Pharmaceuticals Inc | 21 | Q3 2023 | 6.9% |
| HOMOLOGY MEDICINES INC | 21 | Q3 2023 | 3.7% |
View Vivo Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| SINOVAC BIOTECH LTDSold out | August 27, 2018 | 0 | 0.0% |
View Vivo Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-04-22 |
| 13F-HR | 2024-02-07 |
| 13F-HR | 2023-11-08 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-13 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-11 |
View Vivo Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.